LYRA THERAPEUTICS INC (LYRA) Stock News

USA - NASDAQ:LYRA - US55234L2043 - Common Stock

7.67 USD

-0.3 (-3.76%)

Last: 10/10/2025, 8:41:37 PM

7.5999 USD

-0.07 (-0.91%)

After Hours: 10/10/2025, 8:41:37 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LYRA Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Stocktwits - Mentions: DFAS VTI

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

6 days ago - By: Lyra Therapeutics

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

23 days ago - By: Benzinga - Mentions: MBRX ADAP ADTX ALXO ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a month ago - By: Benzinga - Mentions: GSK UPB

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

2 months ago - By: The Motley Fool

Lyra Therapeutics Posts 85% Q2 Loss Drop

2 months ago - By: Zacks Investment Research - Mentions: VVOS

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Lyra Therapeutics

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Zacks Investment Research - Mentions: HRTX

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Lyra Therapeutics

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

4 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

4 months ago - By: Yahoo Finance - Mentions: LUMN HAL MPC PSX ...

Why Lumen Technologies, Inc. (LUMN) Crashed On Wednesday

4 months ago - By: Stocktwits - Mentions: IWM VTI MSFT

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled

4 months ago - By: Lyra Therapeutics

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

5 months ago - By: Lyra Therapeutics

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025